. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: Cancer Prev Res (Phila). 2017 Nov 6;11(1):4–15. doi: 10.1158/1940-6207.CAPR-17-0130

Table 3.

Top signaling pathways in Inflammation and Immunity Transcriptome panel which are activated or inhibited in polyps from patients treated with sulindac-erlotinib compared to patients on placebo

Upstream Regulator	Symbol	Molecule Type	z-score	p-value
Interferon alpha	IFNA	Group	3.063	4.52E-22
Interferon gamma	IFNG	Cytokine	2.965	5.29E-21
Interleukin 12	IL12	Complex	2.675	1.55E-15
Signal transducer and activator of transcription 4	STAT4	Transcription factor	2.403	3.00E-06
Prostaglandin E2	PGE2	Chemical	−2.225	1.52E-05

(+) positive z-score or (−) negative z-score indicates that these pathways are more or less active in patients treated with sulindac-erlotinib versus placebo.